12 Month Price Forecast For CYTK
Distance to CYTK Price Forecasts
CYTK Price Momentum
🤔 Considering Cytokinetics (CYTK)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 10:49 AM UTC
CYTK Analyst Ratings & Price Targets
Based on our analysis of 24 Wall Street analysts, CYTK has a consensus that is bullish. The median price target is $76.00, with forecasts ranging from $60.00 to $120.00. Currently, there are 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
With CYTK currently trading at $50.24, the median price forecast suggests a 51.3% upside. The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 138.9% upside, while Paul Choi at Goldman Sachs provides the most conservative target, suggesting a 19.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYTK Analyst Consensus
CYTK Price Target Range
Latest CYTK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYTK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Dec 2, 2024 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| Nov 21, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $103.00 |
| Nov 20, 2024 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Nov 8, 2024 | RBC Capital | Leonid Timashev | Outperform | Initiates | $80.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Oct 17, 2024 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| Oct 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $120.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Sep 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Sep 5, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $71.00 |
| Sep 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $78.00 |
Cytokinetics Inc (CYTK) Financial Data
Cytokinetics Inc has a market capitalization of $5.97B with a P/E ratio of -9.2x. The company generates $3.22M in trailing twelve-month revenue with a -4,284.1% profit margin.
Revenue growth is +22.5% quarter-over-quarter, while maintaining an operating margin of -30,410.6% and return on equity of +136.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cytokinetics Inc (CYTK) Company Overview
About Cytokinetics Inc
Develops muscle-targeting biopharmaceutical treatments.
Cytokinetics, Incorporated focuses on developing small molecule drug candidates that enhance or inhibit muscle function, primarily targeting heart diseases. The company generates revenue through strategic alliances and collaborations, such as its agreement with Ji Xing Pharmaceuticals for the development of its drugs in specific markets.
The company is in late-stage clinical trials for several drug candidates, including omecamtiv mecarbil and aficamten, which highlight its commitment to addressing debilitating conditions like heart failure and hypertrophic cardiomyopathy. Founded in 1997 and based in South San Francisco, it has a strong pipeline of innovative therapies aimed at improving muscle performance.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
423
CEO
Mr. Robert I. Blum
Country
United States
IPO Year
2004
Website
www.cytokinetics.comCytokinetics Inc (CYTK) Latest News & Analysis
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
4 days agoCytokinetics (CYTK) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for potential impact on the stock.
Cytokinetics' recent earnings report can influence stock performance, impacting investor sentiment and potentially affecting future valuations and growth expectations.
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
9 days agoCYTK has begun enrolling participants for the phase III COMET-HF study, focusing on omecamtiv mecarbil for treating symptomatic heart failure with severely reduced ejection fraction.
Enrollment in a phase III study for omecamtiv mecarbil signals potential advancement in heart failure treatment, which could impact CYTK's stock value and market position.
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
11 days agoCytokinetics' New Drug Application for aficamten, a treatment for obstructive hypertrophic cardiomyopathy, has been accepted by the FDA, with a PDUFA action date set for September 26, 2025.
The FDA's acceptance of Cytokinetics' NDA for aficamten could impact the company's stock price, depending on the drug's approval and market potential in treating HCM.
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
10 days agoCytokinetics has opened enrollment for its Phase 3 trial, COMET-HF, evaluating omecamtiv mecarbil for heart failure with reduced ejection fraction, in collaboration with Duke Clinical Research Institute.
The start of the COMET-HF trial can impact Cytokinetics' stock price and market perception, as successful results may lead to FDA approval and increased revenue potential from omecamtiv mecarbil.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 days agoCytokinetics granted stock options for 34,515 shares and 22,410 RSUs to 7 new employees as an inducement for their employment, effective November 29, 2024.
Cytokinetics is incentivizing new hires with stock options and RSUs, indicating a focus on growth and talent acquisition, which can positively impact stock performance and investor confidence.
Cytokinetics to Participate in December Investor Conferences
11 days agoCytokinetics, Inc. (Nasdaq: CYTK) will participate in December investor conferences, as announced on December 2, 2024.
Cytokinetics' participation in investor conferences could signal potential developments or updates, influencing investor sentiment and stock performance.
Frequently Asked Questions About CYTK Stock
What is Cytokinetics Inc's (CYTK) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Cytokinetics Inc (CYTK) has a median price target of $76.00. The highest price target is $120.00 and the lowest is $60.00.
Is CYTK stock a good investment in 2025?
According to current analyst ratings, CYTK has 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $50.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CYTK stock?
Wall Street analysts predict CYTK stock could reach $76.00 in the next 12 months. This represents a 51.3% increase from the current price of $50.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytokinetics Inc's business model?
Cytokinetics, Incorporated focuses on developing small molecule drug candidates that enhance or inhibit muscle function, primarily targeting heart diseases. The company generates revenue through strategic alliances and collaborations, such as its agreement with Ji Xing Pharmaceuticals for the development of its drugs in specific markets.
What is the highest forecasted price for CYTK Cytokinetics Inc?
The highest price target for CYTK is $120.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 138.9% increase from the current price of $50.24.
What is the lowest forecasted price for CYTK Cytokinetics Inc?
The lowest price target for CYTK is $60.00 from Paul Choi at Goldman Sachs, which represents a 19.4% increase from the current price of $50.24.
What is the overall CYTK consensus from analysts for Cytokinetics Inc?
The overall analyst consensus for CYTK is bullish. Out of 24 Wall Street analysts, 14 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $76.00.
How accurate are CYTK stock price projections?
Stock price projections, including those for Cytokinetics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
